Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease

IntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ecto...

Full description

Bibliographic Details
Main Authors: Audrey Laurain, Isabelle Rubera, Christophe Duranton, Frank Rutsch, Yvonne Nitschke, Elodie Ray, Sandor Vido, Antoine Sicard, Georges Lefthériotis, Guillaume Favre
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/full
id doaj-5e403959d0e6429d81e33fb53be5331f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Audrey Laurain
Audrey Laurain
Audrey Laurain
Isabelle Rubera
Christophe Duranton
Frank Rutsch
Yvonne Nitschke
Elodie Ray
Sandor Vido
Antoine Sicard
Antoine Sicard
Georges Lefthériotis
Georges Lefthériotis
Georges Lefthériotis
Guillaume Favre
Guillaume Favre
Guillaume Favre
spellingShingle Audrey Laurain
Audrey Laurain
Audrey Laurain
Isabelle Rubera
Christophe Duranton
Frank Rutsch
Yvonne Nitschke
Elodie Ray
Sandor Vido
Antoine Sicard
Antoine Sicard
Georges Lefthériotis
Georges Lefthériotis
Georges Lefthériotis
Guillaume Favre
Guillaume Favre
Guillaume Favre
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
Frontiers in Cell and Developmental Biology
alkaline phosphatase activity
hemodialysis
kidney transplant
pyrophosphate
purinergic mechanisms
mineral and bone disorder (CKD-MBD)
author_facet Audrey Laurain
Audrey Laurain
Audrey Laurain
Isabelle Rubera
Christophe Duranton
Frank Rutsch
Yvonne Nitschke
Elodie Ray
Sandor Vido
Antoine Sicard
Antoine Sicard
Georges Lefthériotis
Georges Lefthériotis
Georges Lefthériotis
Guillaume Favre
Guillaume Favre
Guillaume Favre
author_sort Audrey Laurain
title Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
title_short Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
title_full Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
title_fullStr Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
title_full_unstemmed Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
title_sort alkaline phosphatases account for low plasma levels of inorganic pyrophosphate in chronic kidney disease
publisher Frontiers Media S.A.
series Frontiers in Cell and Developmental Biology
issn 2296-634X
publishDate 2020-12-01
description IntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ectopic vascular calcifications belong to these two conditions. This suggests that the purinergic system may be altered in chronic kidney disease with MBD. Therefore, we perform a transversal pilot study in order to compare the determinants of PPi homeostasis and the plasma levels of PPi in patients on dialysis, in KTR and in healthy people.Patients and MethodsWe included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PPi, the renal fractional excretion of PPi (FePPi), nucleoside triphosphate hydrolase (NPP) and ALP activities in plasma. Correlations and comparisons were assessed with non-parametric tests.ResultsLow PPi was found in patients on dialysis [1.11 (0.88–1.35), p = 0.004], in early KTR [0.91 (0.66–0.98), p = 0.0003] and in late KTR [1.16 (1.07–1.45), p = 0.02] compared to controls [1.66 (1.31–1.72) μmol/L]. Arterial calcifications were higher in patients on dialysis than in controls [9 (1–75) vs. 399 (25–526) calcium score/cm2, p < 0.05]. ALP activity was augmented in patients on dialysis [113 (74–160), p = 0.01] and in early KTR [120 (84–142), p = 0.002] compared to controls [64 (56–70) UI/L]. The activity of NPP and FePPi were not different between groups. ALP activity was negatively correlated with PPi (r = −0.49, p = 0.001).DiscussionPatients on dialysis and KTR have low plasma levels of PPi, which are partly related to high ALP activity, but neither to low NPP activity, nor to increased renal excretion of PPi. Further work is necessary to explore comprehensively the purinergic system in chronic kidney disease.
topic alkaline phosphatase activity
hemodialysis
kidney transplant
pyrophosphate
purinergic mechanisms
mineral and bone disorder (CKD-MBD)
url https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/full
work_keys_str_mv AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT isabellerubera alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT christopheduranton alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT frankrutsch alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT yvonnenitschke alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT elodieray alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT sandorvido alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT antoinesicard alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT antoinesicard alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease
_version_ 1724390841296879616
spelling doaj-5e403959d0e6429d81e33fb53be5331f2020-12-08T08:35:23ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2020-12-01810.3389/fcell.2020.586831586831Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney DiseaseAudrey Laurain0Audrey Laurain1Audrey Laurain2Isabelle Rubera3Christophe Duranton4Frank Rutsch5Yvonne Nitschke6Elodie Ray7Sandor Vido8Antoine Sicard9Antoine Sicard10Georges Lefthériotis11Georges Lefthériotis12Georges Lefthériotis13Guillaume Favre14Guillaume Favre15Guillaume Favre16Faculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceNephrology Department, University Hospital, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceDepartment of General Pediatrics, Muenster University Children’s Hospital, Muenster, GermanyDepartment of General Pediatrics, Muenster University Children’s Hospital, Muenster, GermanyDepartment of Vascular Medicine and Surgery, University Hospital, Nice, FranceNephrology Department, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceNephrology Department, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceDepartment of Vascular Medicine and Surgery, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceNephrology Department, University Hospital, Nice, FranceIntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ectopic vascular calcifications belong to these two conditions. This suggests that the purinergic system may be altered in chronic kidney disease with MBD. Therefore, we perform a transversal pilot study in order to compare the determinants of PPi homeostasis and the plasma levels of PPi in patients on dialysis, in KTR and in healthy people.Patients and MethodsWe included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PPi, the renal fractional excretion of PPi (FePPi), nucleoside triphosphate hydrolase (NPP) and ALP activities in plasma. Correlations and comparisons were assessed with non-parametric tests.ResultsLow PPi was found in patients on dialysis [1.11 (0.88–1.35), p = 0.004], in early KTR [0.91 (0.66–0.98), p = 0.0003] and in late KTR [1.16 (1.07–1.45), p = 0.02] compared to controls [1.66 (1.31–1.72) μmol/L]. Arterial calcifications were higher in patients on dialysis than in controls [9 (1–75) vs. 399 (25–526) calcium score/cm2, p < 0.05]. ALP activity was augmented in patients on dialysis [113 (74–160), p = 0.01] and in early KTR [120 (84–142), p = 0.002] compared to controls [64 (56–70) UI/L]. The activity of NPP and FePPi were not different between groups. ALP activity was negatively correlated with PPi (r = −0.49, p = 0.001).DiscussionPatients on dialysis and KTR have low plasma levels of PPi, which are partly related to high ALP activity, but neither to low NPP activity, nor to increased renal excretion of PPi. Further work is necessary to explore comprehensively the purinergic system in chronic kidney disease.https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/fullalkaline phosphatase activityhemodialysiskidney transplantpyrophosphatepurinergic mechanismsmineral and bone disorder (CKD-MBD)